1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Global Biopharmaceutical Market Report & Forecast (2018-2023)

Global Biopharmaceutical Market Report & Forecast (2018-2023)

  • February 2018
  • 210 pages
  • ID: 1007821
  • Format: PDF
  • International Market Analysis Research and Consult

Summary

Table of Contents

The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982.

Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales.

Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada.

Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2018-2023)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2023. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?
Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:
Driving Factors
Restraining Factors
Market Opportunities
Threats

Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:
North America: United States and Canada

Latin America: Mexico, Brazil and Argentina

Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey

Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia

Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:
Total Market Performance
Performance of Various Classes
Performance of Top Players
Market Forecast

Key Questions Answered in this Report:
What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
What are the key opportunities and threats faced by the biopharmaceutical industry?
What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
Which are the world’s largest biopharmaceutical markets?
Which are the world’s fastest growing biopharmaceutical markets?
What is the structure and composition of various biopharmaceutical markets across the globe?
Which are the world’s largest biopharmaceutical segments?
Which are the world’s fastest growing biopharmaceutical segments?
Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on